Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK2793660 in Healthy Subjects
NCT02058407Phase 1Terminated
- Sponsor
- GSK
- Start
- Jan 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK2793660 in bronchiectasis (4 cohorts), sponsored by GSK. Primary endpoints: Safety and tolerability of GSK2793660 as assessed by vital signs, Safety and tolerability of GSK2793660 as assessed by cardiac telemetry and 3 more. Started Jan 2014; status: terminated.
02
Drugs
GSK2793660
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT02058407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058407.